Triglycerides, Diabetes and Cardiovascular Disease Program Project
The Triglycerides, Diabetes and Cardiovascular Disease Program Project (P01HL151328) is funded by the National Heart, Lung, and Blood Institute of the NIH. The overall hypothesis of this Program is that that abnormal assembly, secretion, composition and clearance of triglyceride-rich lipoproteins (TRLs) promote the accumulation of highly atherogenic remnants in atherosclerotic lesions in individuals with type 2 diabetes, and that TRLs and their remnants contribute to cardiovascular disease risk by altering lesion cell populations and functions, thereby increasing atherosclerotic lesion progression and hindering regression
The Program consists of three different projects and three core units
Project 1. Type 2 diabetes, APOC3 and cardiovascular disease
Project Leader: Karin E. Bornfeldt, PhD; Co-Investigators: Jay W. Heinecke, MD, Jenny E. Kanter, PhD, University of Washington
Project 2. ANGPTL3-dependent mechanisms underlying adaptations in hepatic lipoprotein production and clearance
Project Leader: Nathan Stitziel, MD, PhD; Co-Investigator: Nicholas O. Davidson, MD, DSc, Washington University in St. Louis
Project 3. Triglycerides, lipolysis, and vascular inflammation
Project Leader: Ira J. Goldberg, MD; Co-Investigators: Ainara Cabodevilla, PhD, and Edward A. Fisher, MD, PhD, New York University
Core A. Administrative core
Core Leader: Karin E. Bornfeldt, PhD, University of Washington
Core B. Proteomics and lipoprotein characterization core
Core Leader: Tomas Vaisar, PhD, University of Washington
Core C. Atherosclerosis and bioinformatics core
Core Leader: Jenny Kanter, PhD, University of Washington
